肠易激综合征患者血浆及乙状结肠粘膜中VIP及SS的含量

Vasoactive Intestinal Peptide and Somatostatin in the Plasma and Sigmoid Mucosa in Irritable Bowel Syndrome

探讨肠易激综合征 (irritablebowelsyndrome,IBS)患者血浆及乙状结肠粘肠中血管活性肠肽 (VIP)及生长抑素 (SS)有无变化 ,以及它们在IBS发病过程中的可能作用和临床意义。应用放射免疫分析法 (RIA)测定IBS患者血浆及乙状结肠粘膜内VIP及SS的含量 ,并与正常组比较。结果是便秘型IBS患者血浆及乙状结肠粘膜中VIP含量显著高于正常组 (P <0 .0 1) ,腹泻型显著低于正常组 (P <0 .0 5 ) ;SS在IBS各组均显著高于正常组(P <0 .0 5 ) ,而便秘型又显著高于腹泻型 (P <0 .0 5 )。IBS患者存在VIP及SS含量异常 ,且这些异常可能在IBS发病中起一定的作用 ;不同类型IBS患者VIP及SS含量有显著差异 ,说明不同类型IBS在发病机制上可能有其不同的病理学基础。

To investigate the possible role and clinical significance of vasoactive intestinal peptide(VIP) and somatostatin(SS) in the irritable bowel syndrome(IBS), the VIP and SS in the plasma and sigmoid mucosa were measured by radioimmunoassay in the control group and the IBS group.The VIP concentration in the plasma and sigmoid mucosa of the IBS patients with constipation was significantly higher than that of the control group(P<0.01),while that of the IBS patients with diarrhea was signficantly lower than that of the control group(P<0.05).The SS concentration in two sites was significantly elevated in IBS patients of both types and was significantly higher in IBS with constipation than in IBS with diarrhea(P<0.05).Conclusion: The VIP and SS in IBS are abnormal, which might play a role in the pathogenesis of IBS.The plasma and mucosa concenration of VIP and SS in two kinds of IBS patients are significantly different, which indicates that there might be different pathophysiological basis involved in the pathogenesis of the two kinds of IBS patients.